Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cel...
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 22
- Registration Number
- NCT00188825
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 77
- Registration Number
- NCT00149890
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT00149994
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2011-08-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 501
- Registration Number
- NCT00113269
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 274
- Registration Number
- NCT00023244
- Locations
- 🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸The Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.